摘要
目的探讨新辅助化疗对局部晚期宫颈癌细胞周期、增殖的影响及宫颈癌各时期细胞比率和增殖细胞核抗原（PCNA）增殖指数作为新辅助化疗敏感性评价及近期疗效判定指标的可行性。方法将49例局部晚期宫颈癌患者依据新辅助化疗的临床疗效分为有效组和无效组，比较两组宫颈癌各时期细胞比率和PCNA增殖指数。新辅助化疗第2个疗程后4周评价临床疗效。结果49例患者中临床有效39例（有效组），无效10例（无效组）。有效组化疗前后s期细胞比率[（Z1．47±5．21）％、（18．32±5．07）％]均明显高于无效组[（9．63±2．58）％、（10．14±2．32）％]（P〈0．05），有效组化疗前宫颈癌组织中PCNA增殖指数[（81．674±7．14）％]明显高于无效组[（66．99±2．29）％]（P〈0.05）。结论新辅助化疗前s期细胞比率和PCNA增殖指数可作为判定局部晚期宫颈癌化疗敏感性及近期疗效的重要指标。
Objective To investigate the effect of neoadjuvant chemotherapy in locally advanced cervical cancer on cell eycle, proliferation, and evaluate the feasibility of proportion of cell in different phase and proliferating cell nuclear antigen （PCNA） as sensitive indices to assess ehemotherapeutical sensitivity and therapeutical effect. Methods Forty-nine cases of locally advanced cervical eaneer were divided into response group and no-response group according to the clinical efficacy of neoadjuvant chemotherapy. Compared the proportion of cell in different phase and proliferation index of PCNA between two groups. The clinical therapeutic effect was evaluated after 4 weeks in the second neoadjuvant chemotherapy regimen. Results In 49 patients with locally advanced cervical cancer,clinical effective of 39 cases （response group）, no effective of 10 cases （no-response group）. The S-phase proportion of cell in the pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy of response group [ （21.47± 5.21 ）% and （18.32 ± 5.07）%] were higher than those of no-response group [ （9.63±2.58）% and （ 10.14 ±2.32）% ]（P 〈 0.05）. The proliferation index of PCNA of cervical cancer in the pre-neoadjuvant chemotherapy of response group [ （ 81.67 ± 7.14）% ] was higher than that of no-response group [ （66.99± 2.29 ）% ] （P 〈 0.05 ）. Conclusion The S-phase proportion of cell and proliferation index of PCNA in the pre-neoadjuvant chemotherapy are important indexes to assess ehemotherapeutieal sensitivity and therapeutical effect.
出处
《中国医师进修杂志》
2012年第3期3-6,共4页
Chinese Journal of Postgraduates of Medicine
关键词
宫颈肿瘤
细胞周期
增殖细胞核抗原
新辅助化疗
疗效评价
Uterine cervical neoplasms
Cell cycle
Proliferating cell nuclear antigen
Neoadjuvant chemotherapy
Therapeutic evaluation
